Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest.

Our results demonstrate that convalescent plasma is associated with reducing ventilatory requirements in patients with both severe and life-threatening disease, but appears to be most beneficial when administered early in the course of disease when patients meet the criteria for severe illness.